| 达可替尼与吉非替尼一线治疗EGFR突变阳性晚期非小细胞肺癌患者的疗效 |
| |
| 引用本文： | 邬麟,傅睿. 达可替尼与吉非替尼一线治疗EGFR突变阳性晚期非小细胞肺癌患者的疗效[J]. 循证医学, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004 |
| |
| 作者姓名： | 邬麟 傅睿 |
| |
| 作者单位： | 1. 湖南省肿瘤医院、中南大学湘雅医学院附属肿瘤医院胸部内二科,长沙 410006; 2. 广东省人民医院肿瘤中心、广东省医学科学院、广东省肺癌研究所, 广州510080 |
| |
| 摘 要： |
|
| 关 键 词： | 非小细胞肺癌 EGFR突变阳性 达可替尼 吉非替尼 |
Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer |
| |
| WU Lin,FU Rui. Efficacy of Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR Mutation Positive Non-Small Cell Lung Cancer[J]. The Journal of Evidence-Based Medicine, 2019, 19(4): 212-216. DOI: 10.12019/j.issn.1671-5144.2019.04.004 |
| |
| Authors: | WU Lin FU Rui |
| |
| Affiliation: | Division Two, Department of Thoracic Oncology, Hunan Cancer Hospital, Affiliated Tumor Hospital, Xiangya Medical College, Central South University,Changsha 410006, China |
| |
| Abstract: | |
| |
| Keywords: | non-small cell lung cancer EGFR-mutation positive Dacomitinib Gefitinib |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
|
